TWI428129B - 用於治療創傷後壓迫症之四氫喹啉衍生物 - Google Patents
用於治療創傷後壓迫症之四氫喹啉衍生物 Download PDFInfo
- Publication number
- TWI428129B TWI428129B TW097139093A TW97139093A TWI428129B TW I428129 B TWI428129 B TW I428129B TW 097139093 A TW097139093 A TW 097139093A TW 97139093 A TW97139093 A TW 97139093A TW I428129 B TWI428129 B TW I428129B
- Authority
- TW
- Taiwan
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- phenyl
- acceptable salt
- Prior art date
Links
- 125000000147 tetrahydroquinolinyl group Chemical class N1(CCCC2=CC=CC=C12)* 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 12
- -1 2-(4-trifluoromethyl-phenyl)-ethyl Chemical group 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- DKMACHNQISHMDN-RPLLCQBOSA-N Almorexant Chemical compound C([C@H]1C2=CC(OC)=C(OC)C=C2CCN1[C@@H](C(=O)NC)C=1C=CC=CC=1)CC1=CC=C(C(F)(F)F)C=C1 DKMACHNQISHMDN-RPLLCQBOSA-N 0.000 claims description 2
- JIKSXSUBAADKKK-UHFFFAOYSA-N 1h-indol-2-amine;hydrochloride Chemical compound Cl.C1=CC=C2NC(N)=CC2=C1 JIKSXSUBAADKKK-UHFFFAOYSA-N 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 21
- 208000019901 Anxiety disease Diseases 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 230000024188 startle response Effects 0.000 description 6
- 229940123730 Orexin receptor antagonist Drugs 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 229940049706 benzodiazepine Drugs 0.000 description 4
- 230000006397 emotional response Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 208000029364 generalized anxiety disease Diseases 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- DKMACHNQISHMDN-UHFFFAOYSA-N 2-[6,7-dimethoxy-1-[2-[4-(trifluoromethyl)phenyl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]-n-methyl-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(C(=O)NC)N1CCC2=CC(OC)=C(OC)C=C2C1CCC1=CC=C(C(F)(F)F)C=C1 DKMACHNQISHMDN-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108050000742 Orexin Receptor Proteins 0.000 description 1
- 102000008834 Orexin receptor Human genes 0.000 description 1
- 206010033670 Panic reaction Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2007054130 | 2007-10-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200932231A TW200932231A (en) | 2009-08-01 |
| TWI428129B true TWI428129B (zh) | 2014-03-01 |
Family
ID=40467356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW097139093A TWI428129B (zh) | 2007-10-10 | 2008-10-09 | 用於治療創傷後壓迫症之四氫喹啉衍生物 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9532985B2 (enExample) |
| EP (1) | EP2207550B1 (enExample) |
| JP (1) | JP5883222B2 (enExample) |
| KR (1) | KR101733247B1 (enExample) |
| CN (1) | CN101820878B (enExample) |
| AR (1) | AR068768A1 (enExample) |
| AU (1) | AU2008309194B2 (enExample) |
| BR (1) | BRPI0818617A2 (enExample) |
| CA (1) | CA2699504C (enExample) |
| CY (1) | CY1114799T1 (enExample) |
| DK (1) | DK2207550T3 (enExample) |
| EA (1) | EA017443B1 (enExample) |
| ES (1) | ES2444418T3 (enExample) |
| HR (1) | HRP20140214T1 (enExample) |
| IL (1) | IL204838A (enExample) |
| MA (1) | MA31800B1 (enExample) |
| MX (1) | MX2010003711A (enExample) |
| MY (1) | MY153044A (enExample) |
| NZ (1) | NZ585086A (enExample) |
| PE (1) | PE20091010A1 (enExample) |
| PL (1) | PL2207550T3 (enExample) |
| PT (1) | PT2207550E (enExample) |
| SI (1) | SI2207550T1 (enExample) |
| TW (1) | TWI428129B (enExample) |
| UA (1) | UA99150C2 (enExample) |
| WO (1) | WO2009047723A2 (enExample) |
| ZA (1) | ZA201003251B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010513466A (ja) | 2006-12-22 | 2010-04-30 | アクテリオン ファーマシューティカルズ リミテッド | ５，６，７，８−テトラヒドロ−イミダゾ［１，５−ａ］ピラジン誘導体 |
| US20110105514A1 (en) | 2008-06-25 | 2011-05-05 | Hamed Aissaoui | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds |
| EP2402322A1 (en) | 2010-07-02 | 2012-01-04 | Actelion Pharmaceuticals Ltd. | 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist |
| KR101802726B1 (ko) | 2010-08-24 | 2017-11-29 | 액테리온 파마슈티칼 리미티드 | 오렉신 수용체 안타고니스트로서의 프롤린 술폰아미드 유도체 |
| SI2626350T1 (sl) | 2010-09-22 | 2015-09-30 | Eisai R&D Management Co., Ltd. | Spojina ciklopropana |
| WO2012063207A1 (en) | 2010-11-10 | 2012-05-18 | Actelion Pharmaceuticals Ltd | Lactam derivatives useful as orexin receptor antagonists |
| WO2012085852A1 (en) | 2010-12-22 | 2012-06-28 | Actelion Pharmaceuticals Ltd | 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides |
| KR101873083B1 (ko) | 2011-02-18 | 2018-06-29 | 이도르시아 파마슈티컬스 리미티드 | 오렉신 길항제로서 유용한 신규 피라졸 및 이미다졸 유도체 |
| WO2012114252A1 (en) | 2011-02-21 | 2012-08-30 | Actelion Pharmaceuticals Ltd | Novel indole and pyrrolopyridine amides |
| WO2013050938A1 (en) | 2011-10-04 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives |
| DK2776430T3 (en) | 2011-11-08 | 2016-05-09 | Actelion Pharmaceuticals Ltd | 2- (1,2,3-triazol-2-yl) benzamide and 3- (1,2,3-triazol-2-yl) PICOLINAMIDDERIVATER AS orexin receptor antagonists |
| PL2855453T3 (pl) | 2012-06-04 | 2017-05-31 | Actelion Pharmaceuticals Ltd. | Pochodne benzimidazoloproliny |
| JP6244365B2 (ja) | 2012-10-10 | 2017-12-06 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ［オルトビ−（ヘテロ−）アリール］−［２−（メタビ−（ヘテロ−）アリール）−ピロリジン−１−イル］−メタノン誘導体であるオレキシン受容体アンタゴニスト |
| EP2970241A1 (en) | 2013-03-12 | 2016-01-20 | Actelion Pharmaceuticals Ltd. | Azetidine amide derivatives as orexin receptor antagonists |
| EA030137B1 (ru) | 2013-12-03 | 2018-06-29 | Идорсиа Фармасьютиклз Лтд | Кристаллическая форма (s)-(2-(6-хлор-7-метил-1н-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора |
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| LT3077391T (lt) | 2013-12-04 | 2018-10-25 | Idorsia Pharmaceuticals Ltd | Benzimidazolo prolino darinių panaudojimas |
| JP6659681B2 (ja) | 2014-10-23 | 2020-03-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 不眠症を治療するための組成物および方法 |
| JP7179049B2 (ja) * | 2017-08-01 | 2022-11-28 | ベルゲン ファーマシューティカル、 エルエルシー | オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途 |
| WO2020007964A1 (en) | 2018-07-05 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives |
| WO2020007977A1 (en) | 2018-07-06 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 7-trifluoromethyl-[1,4]diazepan derivatives |
| WO2020099511A1 (en) | 2018-11-14 | 2020-05-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-2-methyl-morpholine derivatives |
| AR129309A1 (es) | 2022-05-13 | 2024-08-07 | Idorsia Pharmaceuticals Ltd | Derivados de hidrazina-n-carboxamida cíclica sustituida con tiazoloaril-metilo |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02008797A (es) | 2000-03-14 | 2005-09-08 | Actelion Pharmaceuticals Ltd | Derivados de 1,2,3,4-tetrahidroisoquinolina. |
| CA2518945A1 (en) * | 2003-03-26 | 2004-10-07 | Actelion Pharmaceuticals Ltd. | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists |
| WO2005118548A1 (en) * | 2004-03-01 | 2005-12-15 | Actelion Pharmaceuticals Ltd | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
| US7501395B2 (en) * | 2005-04-25 | 2009-03-10 | Eisai R & D Management Co., Ltd. | Method of screening for antianxiety drugs |
| AU2007226203A1 (en) * | 2006-03-15 | 2007-09-20 | Actelion Pharmaceuticals Ltd | Tetrahydroisoquinoline derivatives to enhance memory function |
| EP2402322A1 (en) | 2010-07-02 | 2012-01-04 | Actelion Pharmaceuticals Ltd. | 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist |
-
2008
- 2008-10-07 PE PE2008001739A patent/PE20091010A1/es not_active Application Discontinuation
- 2008-10-09 HR HRP20140214AT patent/HRP20140214T1/hr unknown
- 2008-10-09 NZ NZ585086A patent/NZ585086A/en not_active IP Right Cessation
- 2008-10-09 MX MX2010003711A patent/MX2010003711A/es active IP Right Grant
- 2008-10-09 CN CN2008801113334A patent/CN101820878B/zh not_active Expired - Fee Related
- 2008-10-09 PT PT88079371T patent/PT2207550E/pt unknown
- 2008-10-09 BR BRPI0818617-0A patent/BRPI0818617A2/pt not_active Application Discontinuation
- 2008-10-09 JP JP2010528515A patent/JP5883222B2/ja not_active Expired - Fee Related
- 2008-10-09 SI SI200831152T patent/SI2207550T1/sl unknown
- 2008-10-09 AU AU2008309194A patent/AU2008309194B2/en not_active Ceased
- 2008-10-09 PL PL08807937T patent/PL2207550T3/pl unknown
- 2008-10-09 MY MYPI2010001561A patent/MY153044A/en unknown
- 2008-10-09 US US12/681,802 patent/US9532985B2/en not_active Expired - Fee Related
- 2008-10-09 CA CA2699504A patent/CA2699504C/en active Active
- 2008-10-09 ES ES08807937.1T patent/ES2444418T3/es active Active
- 2008-10-09 TW TW097139093A patent/TWI428129B/zh not_active IP Right Cessation
- 2008-10-09 DK DK08807937.1T patent/DK2207550T3/da active
- 2008-10-09 EA EA201000557A patent/EA017443B1/ru not_active IP Right Cessation
- 2008-10-09 EP EP08807937.1A patent/EP2207550B1/en active Active
- 2008-10-09 AR ARP080104422A patent/AR068768A1/es unknown
- 2008-10-09 UA UAA201005122A patent/UA99150C2/ru unknown
- 2008-10-09 KR KR1020107010186A patent/KR101733247B1/ko not_active Expired - Fee Related
- 2008-10-09 WO PCT/IB2008/054138 patent/WO2009047723A2/en not_active Ceased
-
2010
- 2010-04-06 IL IL204838A patent/IL204838A/en active IP Right Grant
- 2010-04-30 MA MA32806A patent/MA31800B1/fr unknown
- 2010-05-07 ZA ZA2010/03251A patent/ZA201003251B/en unknown
-
2014
- 2014-02-04 CY CY20141100085T patent/CY1114799T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI428129B (zh) | 用於治療創傷後壓迫症之四氫喹啉衍生物 | |
| JP4212149B2 (ja) | 医薬 | |
| TWI243678B (en) | A pharmaceutical composition for the treatment and/or prophylaxis of conditions characterized by altered bowel function and/or visceral pain in human or non-human mammals | |
| CA2869269C (en) | Use of ccr3-inhibitors | |
| JP2004525179A (ja) | ジペプチジルペプチダーゼｉｖ阻害剤でのｉｉ型糖尿病の処置 | |
| WO2011123719A2 (en) | Use of faah inhibitors for treating abdominal, visceral and pelvic pain | |
| CN111214468A (zh) | 新型药物组合物及其用途 | |
| EA015483B1 (ru) | ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ | |
| CA2258696A1 (en) | A method of treating liver disease and like indications with vasodilating agents | |
| CZ2004524A3 (cs) | Agonisté nikotinového acetylcholinového receptoru v léčbě syndromu neklidných nohou | |
| GB2291592A (en) | Pharmaceutical compositions comprising a bicycloheptane derivative | |
| KR102303154B1 (ko) | 실데나필 및 rock 저해제를 포함하는 뇌졸중 치료용 약학적 조성물 | |
| CN104582704A (zh) | 含伊马替尼或其药学上可接受的盐作为有效成分的用于治疗或预防血管渗透性疾病的组合物 | |
| HK1145440B (en) | Tetrahydroquinoline derivatives for treating post-traumatic stress disorders | |
| JP2008512440A (ja) | ジアザビシクロ化合物含有ベンゾイソオキサゾールを用いる気分障害の治療方法 | |
| CN102026987B (zh) | 疼痛治疗药 | |
| WO2020030089A1 (zh) | 苯并间二氧杂环戊烯衍生物在治疗与胃肠蠕动障碍相关疾病中的应用 | |
| CA2170289C (en) | A method of treating liver disease and like indications with vasodilating agents | |
| WO2025102989A1 (zh) | 靶向O-GlcNAc糖苷水解酶抑制剂促进髓鞘再生 | |
| CN121177493A (zh) | 一种药物组合及其应用 | |
| TW201924677A (zh) | 苯并咪唑衍生物用於夜間酸突破的用途 | |
| AU9142098A (en) | A method of treating liver disease and like indications with vasodilating agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |